Summit Therapeutics' leading candidate is showing promise in a key oncology market. Three years ago, Summit Therapeutics ...

Sarepta Therapeutics has rejected a call by the Food and Drug Administration to stop shipments of its muscular dystrophy drug.

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

Shares of Viking Therapeutics soared last year on high hopes for its obesity drug VK2735. The stock stumbled beginning in ...

One of the big reasons to like Pfizer (NYSE: PFE) today is its huge 7.1% dividend yield. Pfizer competitor Merck (NYSE: MRK) ...

An NHS surgeon has delivered his 'hot take' on why weight-loss jabs like Wegovy and Mounjaro are causing 'Ozempic babies' to be born.

Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...

Ozempic and Mounjaro are both very popular for weight loss at the minute, but there's one big difference between the two ...

UCSF researchers find that two FDA-approved cancer drugs significantly improve memory in Alzheimer’s mouse models and reduce ...

Researchers followed 60,000 adults aged 40 and older—who took various types of antidiabetic medication—for seven years ...

Shares of drug developer Sarepta Therapeutics surged more than 20% in morning trading, rising after the late-Wednesday news that the company would shrink its workforce and pause several developmental ...

Anthem Biosciences Ltd's shares debuted with a 27% premium over the issue price, initially trading at Rs 723.10 on the BSE.